Notification report

Full notification file

General information

Notification Number

Member State to which the notification was sent

Date of acknowledgement from the Member State Competent Authority

Title of the Project
A phase I/II trial investigating LOAd703 in combination with atezolizumab in malignant melanoma

Proposed period of release:
01/01/2020 to 31/12/2022

Name of the Institute(s) or Company(ies)
Lokon Pharma AB, ;

3. Is the same GMO release planned elsewhere in the Community?

Has the same GMO been notified elsewhere by the same notifier?

If yes, notification number(s):

GMO characterization

GMO is a:
DNA Virus

Identity of the GMO:
LOAd703 is an adenovirus group C serotype 5 with changed fiber to serotype 35 in genome region L5. It has deletions in E1 and E3 genome regions: E1Adelta24, E3deltagp19K and E3delta6.7K. Ahead of E1A it has 8 E2F sites (4 palindromes) and one Sp-1 site. A transgene cassette is inserted after L5 including a CMV promoter, human full length 4-1BBL and an extracellular and intracellular domain of human CD40L fused to an isoleucine zipper domain (TMZCD40L) (Eriksson et al, Clin Cancer Res, 2017, 23:5846-5857).

Information relating to the recipient or parental organisms from wich the GMO is derived
Common NameGenusSpeciesSubspeciesStrainPathovar
Ad5Mastadenovirushuman adenovirussubgroup Cserotype 5-

European Commission administrative information

Consent given by the Member State Competent Authority:
Not known